for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ジー・エス・ケー

GSK.L

現在値

1,770.40GBp

変化

-22.60(-1.26%)

出来高

530,450

本日のレンジ

1,762.80

 - 

1,777.40

52週レンジ

1,215.83

 - 

1,817.00

∙ 約20分前の相場を表示しています。

適時開示

Ideaya Announces Development Candidate Nomination Of A Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With Gsk

June 28 (Reuters) - IDEAYA Biosciences Inc <IDYA.O>::IDEAYA ANNOUNCES DEVELOPMENT CANDIDATE NOMINATION OF A POTENTIAL FIRST-IN-CLASS POL THETA HELICASE INHIBITOR IN COLLABORATION WITH GSK.IDEAYA - ON POTENTIAL COMMERCIALIZATION, CO ELIGIBLE TO RECEIVE UP TO $475 MILLION OF COMMERCIAL MILESTONES & TIERED ROYALTIES ON GLOBAL NET SALES BY GSK.IDEAYA-OBSERVED COMPLETE RESPONSES IN PRECLINICAL COMBINATION STUDIES OF POL THETA HELICASE DC WITH NIRAPARIB IN MULTIPLE IN VIVO PDX & CDX HRD MODELS.IDEAYA - CO AND GSK ARE TARGETING IND SUBMISSION FOR POL THETA HELICASE DC, SUBJECT TO COMPLETION OF ONGOING PRECLINICAL AND IND-ENABLING STUDIES.

GSK Says Japan Accepts Shingrix Regulatory Submission To Prevent Shingles In At-Risk Adults

June 28 (Reuters) - GSK plc <GSK.L>::GSK PLC - GSK FILES SHINGRIX 18+ AT RISK INDICATION IN JAPAN.GSK - JAPAN ACCEPTS SHINGRIX REGULATORY SUBMISSION TO PREVENT SHINGLES IN AT-RISK ADULTS AGED 18 YEARS AND OLDER.

GSK Announces £1 Billion Research And Development Investment

June 23 (Reuters) - GSK plc <GSK.L>::GSK - £1 BILLION RESEARCH AND DEVELOPMENT INVESTMENT OVER TEN YEARS TO GET AHEAD OF INFECTIOUS DISEASES IN LOWER-INCOME COUNTRIES.GSK - NEW INVESTMENT SUPPORTS FURTHER INNOVATION IN MALARIA, TUBERCULOSIS, HIV, WITH EMPHASIS ON NEGLECTED TROPICAL DISEASES & ANTI-MICROBIAL RESISTANCE.GSK- TO MAINTAIN DONATIONS OF ALBENDAZOLE UNTIL ELIMINATION OF LYMPHATIC FILARIASIS, DOUBLE PRODUCTION OF ADJUVANT FOR USE IN RTS,S MALARIA VACCINE.GSK - GSK GLOBAL HEALTH RESEARCH AND DEVELOPMENT HUBS ARE PROGRESSING MORE THAN 30 POTENTIAL NEW VACCINES AND MEDICINES, TARGETING 13 HIGH-BURDEN INFECTIOUS DISEASES.GSK- TO DELIVER AGAINST TARGETS, GSK FORMED DEDICATED, NON-COMMERCIAL GLOBAL HEALTH UNIT FOR WHICH SUCCESS IS MEASURED BY HEALTH IMPACT ALONE.GSK: INVESTMENT TO SUPPORT CO'S EFFORTS TO REDUCE ANTIBIOTIC RESISTANCE BY ADVANCING PIPELINE FOR VACCINES.

GSK Reports Positive Phase III Data For RSV Vaccine Candidate

June 10 (Reuters) - GSK <GSK.L>::GSK PLC - POSITIVE PHASE III DATA FOR GSK'S RSV OA VACCINE.GSK - FIRST RSV VACCINE CANDIDATE TO SHOW STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL EFFICACY IN ADULTS AGED 60 YEARS AND ABOVE.GSK: MAGNITUDE OF EFFECT OBSERVED WAS CONSISTENT ACROSS RSV A AND B STRAINS, KEY SECONDARY ENDPOINTS AND IN THOSE AGED 70 YEARS AND ABOVE.GSK - ENGAGEMENT WITH REGULATORS TO START IMMEDIATELY WITH ANTICIPATED REGULATORY SUBMISSIONS IN H2 2022.

GSK Plc Says Demerger And Listing Of Haleon Expected In July

May 30 (Reuters) - GSK Plc <GSK.L>::GSK PLC - FURTHER APPOINTMENTS TO DESIGNATE HALEON BOARD.GSK - DEMERGER AND LISTING OF HALEON EXPECTED IN JULY 2022.GSK - APPOINTMENTS OF ASMITA DUBEY, MARIE-ANNE AYMERICH AND BRYAN SUPRAN TO DESIGNATE HALEON BOARD,.

Glaxosmithkline Confirms It Has Changed Its Name To GSK PLC

May 16 (Reuters) - GlaxoSmithKline PLC <GSK.L>::GLAXOSMITHKLINE PLC - CHANGE OF NAME TO GSK PLC.GSK - LONDON STOCK EXCHANGE AND NEW YORK STOCK EXCHANGE WILL REFLECT CHANGE OF NAME IN DUE COURSE..GSK - CONFIRMS ITS NAME HAS CHANGED FROM GLAXOSMITHKLINE PLC TO GSK PLC..

GlaxoSmithKline Says 38% Of Votes Cast At AGM Against Resolution To Approve The Remuneration Policy

May 4 (Reuters) - GlaxoSmithKline PLC <GSK.L>::GLAXOSMITHKLINE PLC - RESULT OF AGM.GSK - ALL 28 RESOLUTIONS PASSED AT AGM.GSK - 38.24% OF SHAREHOLDERS OF VOTES CAST AT AGM AGAINST RESOLUTION TO APPROVE THE REMUNERATION POLICY.

GSK Says Vishal Sikka Will Join Co's Board As Non-Executive Director

May 4 (Reuters) - GlaxoSmithKline PLC <GSK.L>::GSK - VISHAL SIKKA, FOUNDER AND CEO OF VIANAI SYSTEMS, WILL JOIN BOARD OF COMPANY AS A NON-EXECUTIVE DIRECTOR.GLAXOSMITHKLINE PLC - DIRECTORATE CHANGE.GSK - A FURTHER NON-EXECUTIVE APPOINTMENT, WITH DEEP BIOPHARMA EXPERTISE, IS EXPECTED IN JULY 2022.

Sanofi Q1 Business Operating Income Up At EUR 2.42 Billion

April 28 (Reuters) - SANOFI SA <SASY.PA>::Q1 IFRS NET SALES REPORTED EUR 9.67 BILLION +12.6% YOY.Q1 BUSINESS OPERATING INCOME EUR 3.07 BILLION +16.2% YOY.Q1 BUSINESS NET INCOME EUR 2.42 BILLION +20.2% YOY.Q1 BUSINESS EPS EUR 1.94, +20.5% YOY.CO DEVELOPPING WITH GSK NEXT-GENERATION BOOSTER COVID VACCINE DESIGNED TO PROVIDE BROAD PROTECTION AGAINST ALL VARIANTS OF CONCERN : DATA (VAT02 COHORT 2) IS EXPECTED TO BE COMMUNICATED IN Q2 2022.END-Q1 FREE CASH FLOW BEFORE RESTRUCTURING, ACQUISITIONS AND DISPOSALS DECREASED BY 15.5% TO EUR 1,998 MILLION.EXPECTS 2022 BUSINESS EPS TO GROW LOW DOUBLE-DIGIT AT CER, BARRING UNFORESEEN MAJOR ADVERSE EVENTS.APPLYING AVERAGE APRIL 2022 EXCHANGE RATES, POSITIVE CURRENCY IMPACT ON 2022 BUSINESS EPS IS ESTIMATED TO BE BETWEEN +4% TO +5%.

GSK CEO Says Co Interested In Endemic COVID Vaccine Market - Media Call

April 27 (Reuters) - GlaxoSmithKline <GSK.L> CEO::SAYS GLOBAL SUPPLY OF COVID-19 VACCINES VERY STRONG, BUT CO INTERESTED IN BEING ABLE TO CONTRIBUTE TO ENDEMIC MARKET IN DUE COURSE - MEDIA CALL.SAYS UNDERLYING DEMAND FOR SHINGRIX IS GOOD - MEDIA CALL.SAYS CO NOT ANTICIPATING ANY SIGNIFICANT IMPACT ON ITS DEVELOPMENT PROGRAMS LONG TERM FROM DISRUPTION OF TRIALS IN RUSSIA AND UKRAINE - MEDIA CALL.Further company coverage: GSK.L. ((Reuters.Briefs@thomsonreuters.com;)).

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up